Last reviewed · How we verify
DKF-313
DKF-313 is a small molecule that targets the molecular target.
DKF-313 is a small molecule that targets the molecular target. Used for Unknown.
At a glance
| Generic name | DKF-313 |
|---|---|
| Sponsor | Dongkook Pharmaceutical Co., Ltd. |
| Drug class | Unknown |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Unknown |
| Phase | Phase 3 |
Mechanism of action
DKF-313 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Unknown
Common side effects
Key clinical trials
- Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia (PHASE3)
- Safety and Pharmacokinetic Characteristics of DKF-313 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DKF-313 CI brief — competitive landscape report
- DKF-313 updates RSS · CI watch RSS
- Dongkook Pharmaceutical Co., Ltd. portfolio CI